Clinical results of Intraductal Meibomian gland probing combined with intense pulsed light in treating patients with refractory obstructive Meibomian gland dysfunction: a randomized controlled trial

Table 1 Clinical parameters before and after treatment in refractory O-MGD patients

	Group I (IPL)		P	Group II (MGP)		P	Group III (MGP-IPL)		P
Scores	before	after		before	after		before	after
SPEED	16.14 ± 3.53	12.43 ± 3.84	<0.001	17.13 ± 3.23	11.93 ± 3.26	<0.001	18.00 ± 3.51	9.00 ± 1.80	<0.001
TBUT	2.66 ± 0.88	4.35 ± 0.88	<0.001	3.21 ± 0.98	4.81 ± 2.03	<0.001	2.78 ± 1.00	6.61 ± 1.57	<0.001
CFS	2.29 ± 2.71	0.96 ± 2.10	<0.001	2.13 ± 2.34	0.80 ± 1.35	<0.001	2.79 ± 2.51	0.29 ± 0.71	<0.001
Meibum grade	7.11 ± 4.57	20.82 ± 11.83	0.003	8.23 ± 3.15	26.57 ± 11.63	<0.001	6.64 ± 3.41	41.11 ± 10.26	<0.001
Lid telangiectasia	2.36 ± 0.49	1.43 ± 0.50	0.006	2.27 ± 0.45	1.73 ± 0.64	0.001	2.54 ± 0.51	1.07 ± 0.26	0.001
Orifice abnormality	2.14 ± 0.52	1.54 ± 0.51	<0.001	2.30 ± 0.60	1.80 ± 0.85	<0.001	2.00 ± 0.67	1.29 ± 0.46	<0.001
Lid tenderness	1.79 ± 0.79	1.36 ± 0.49	0.003	2.13 ± 0.57	0.57 ± 0.63	0.001	1.93 ± 0.81	0.36 ± 0.49	<0.001

P values were determined with a paired Wilcoxon test
“AFTER” was determined as 3 weeks after final treatment for groups I and III and 12 weeks after final treatment for group II

ISSN: 1471-2415